You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. TOPIC 369: NOVEL DOSING AND DISPENSING SYSTEM FOR MULTIPARTICULATE CANCER DRUGS

    SBC: HS-DESIGN, INC            Topic: NCI

    Oncology drugs continue to advance at a rapid pace with many therapies delivered orally as tablets or capsulesSmaller childrenhowevercannot swallow tablets or capsulesFor these drugs to be used in the pediatric population they need to be reformulatedTraditionally this has meant creating a liquid suspensionchewableor rapid dissolve tabletCancer medicationshoweveroften have terrible taste profiles t ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Radiation Sterilizable, RFID Tagged Vials for Biomedical Samples

    SBC: BIOTILLION LLC            Topic: OD

    Abstract The Specific Aim of this Phase IIb (Phase II competitive renewal) SBIR proposal is to advance the prototypes we developed under our Phase I and II SBIR grants into commercial production. We will produce SBS-96 format radiation sterilizable electronically tagged sample vials that can be read at ultra-low temperatures. Hundreds of millions of SBS-96 vials are sold each year and each of thes ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction

    SBC: VASADE BIOSCIENCES, INC.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT The most significant advance in the treatment of Myocardial Infarction (MI) has been reperfusion therapy, which must be applied immediately after the MI diagnosis has been made. Despite the thousands of studies on drug therapies designed to reduce the size of the MI, most have failed in clinical trials. Our hypothesis is that a major reason why these drugs failed is that t ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Protein therapeutic to facilitate healing of chronic wounds.

    SBC: TRIM-EDICINE INC            Topic: 300

    Project Summary This proposal builds upon the advances from the SBIR-Phase I program (R43GM123887), targeting the development of recombinant human MG53 (rhMG53), a novel tissue repair protein, as a topical therapeutic agent to facilitate healing of chronic wounds. Wound care represents a challenging problem to the public health, as no effective treatments for chronic non-healing wounds are availab ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Feasibility of a mobile parent-based intervention to reduce alcohol use by highschool seniors

    SBC: REAL PREVENTION LLC            Topic: 350

    The goal of this Phase II SBIR is to provide an efficient, engaging, and effective means to enhance parents’ ability to reduce prevalence of alcohol use and consequences, and other substance use through the development and evaluation of Parenting Now (PN). PN is a brief, interactive, self-paced, and digital curriculum for parents of high-school-aged adolescents, a frequently neglected population ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Cervix monitor for risk assessment of spontaneous preterm delivery

    SBC: ADVANCED TACTILE IMAGING INC            Topic: NICHD

    PROJECT SUMMARY Preterm delivery is a leading cause of infant mortality and morbidity. It is estimated that annually about 15 million infants are born preterm. Across 184 countries, the rate of preterm birth ranges from 5% to 18%. In most countries, the rate of preterm birth has risen in the recent decades, and now preterm birth represents the most common cause of neonatal mortality. It is the sec ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. An Improved Method of Delivering a Sclerosing Agent for the Treatment of a Malignant Pleural Effusion.

    SBC: TDL INNOVATIONS LLC            Topic: 100

    Project Summary / Abstract. We are developing an improved clinical method to treat patients with malignant pleural effusions (MPE), a serious condition that occurs in 150,00-175,000 patients in the US each year, affecting between 7 to 15% of all cancer patients. MPE results in an excessive accumulation of liquid in the pleural cavity, frequently leaving the patient to suffer from shortness of brea ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. A user-friendly point-of-care device for G6PDH determination

    SBC: ANALYTICAL DIAGNOSTIC SOLUTIONS INC            Topic: NIAID

    Abstract Malaria caused by Plasmodium vivax threatens over 2 billion people globally and sickens tens of millions annually. Radical cure for P. vivax malaria includes therapy aimed both at the acute attack (blood schizontocidal) and against future attacks (hypnozoitocidal). The only hypnozoitocides available are 8-aminoquinolines such as primaquine or tafenoquine. However, clinicians often do not ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Non-Invasive Venous Waveform Analysis (NIVA) in patients with Heart Failure (HF)

    SBC: Volumetrix, LLC            Topic: NHLBI

    Volume overload (congestion) occurs in patients with heart failure (HF) and is the leading cause of hospitalization in the elderly worldwide. Unfortunately, clinical signs and symptoms; laboratory values; and existing diagnostic tools are unreliable in providing accurate assessment of volume status. Using a unique physiologic signal, Non-Invasive Venous waveform Analysis (NIVA), VoluMetrix has dev ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Restoring Beta-lactam efficacy against methicillin-resistant Staphylococci

    SBC: Prokaryotics, Inc.            Topic: NIAID

    Methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE) are a major cause of bloodstream infections in the hospital and in the community. Indeed, MRSA remains the second leading cause of mortality by drug-resistant bacterial pathogens in the USA. Although two mechanistically novel antibiotic classes exist to treat such infections (Daptomycin; ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government